📣 VC round data is live. Check it out!

Senvest Capital Valuation Multiples

Discover Senvest Capital's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Platinum Capital, Wereldhave Belgium, Mogan Enerji, Qualitas Real Estate and more.

Senvest Capital Overview

About Senvest Capital

Senvest Capital Inc holds and manages a portfolio of equity and real estate investments that are located predominantly in the United States. Its investments in both publicly traded and privately-held companies are mainly carried out through Senvest International, while its investments in real estate are mainly carried out through PPI, Senvest Argentina, and Senvest Equities. The company also provides services to the two Funds which are targeted toward institutions and high net worth individuals. Its real estate holdings are located mainly in the United States. The company operates in USA, Canada, European Union,. and Others. Majority of revenue from USA.


Founded

1968

HQ

Canada

Employees

30

Financials (FY)

Revenue: $370M
Net Income: $108M

EV

$702M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Senvest Capital Financials

Senvest Capital reported last fiscal year revenue of $370M.

In the same fiscal year, Senvest Capital generated $108M in net income.


Senvest Capital P&L

In the most recent fiscal year, Senvest Capital reported revenue of $370M and net income of $108M.

Senvest Capital is profitable as of last fiscal year, with net margin of 29%.

See analyst estimates for Senvest Capital
Last FY202320242025202620272028
Revenue$370M$239M$628M$370M
Net Profit$108M$60M$187M$108M
Net Margin29%25%30%29%

Financial data powered by Morningstar, Inc.

Senvest Capital Stock Performance

Senvest Capital has current market cap of $702M, and enterprise value of $702M.

Market Cap Evolution


Senvest Capital's stock price is $289.87.

Senvest Capital share price decreased by 0.3% in the last 30 days, and increased by 19.9% in the last year.

Senvest Capital has an EPS (earnings per share) of $44.56.

See more trading valuation data for Senvest Capital
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$702M$702M-0.3%-0.3%20.2%19.9%$44.56

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Senvest Capital Valuation Multiples

Senvest Capital trades at 1.9x EV/Revenue multiple.

See NTM and 2027E valuation multiples for Senvest Capital

Senvest Capital Financial Valuation Multiples

As of June 3, 2026, Senvest Capital has market cap of $702M and EV of $702M.

Senvest Capital has a P/E ratio of 6.5x.

Last FY202320242025202620272028
EV/Revenue1.9x2.9x1.1x1.9x
P/E6.5x11.6x3.8x6.5x
EV/FCF2.9x11.5x4.8x2.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Senvest Capital Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Senvest Capital Margins & Growth Rates

In the most recent fiscal year, Senvest Capital reported net margin of 29%.

See estimated margins and future growth rates for Senvest Capital

Senvest Capital Margins

Last FY20242025202720282029
Net Margin29%30%29%
FCF Margin65%23%65%

Senvest Capital Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth163%(41%)
Net Profit Growth209%(42%)
FCF Growth138%65%

Data powered by FactSet, Inc. and Morningstar, Inc.

Senvest Capital Operational KPIs

Senvest Capital's revenue per employee in the last FY averaged $12.3M, while opex per employee averaged $8.1M for the same period.

Access forward-looking KPIs for Senvest Capital
Last FY202320242025202620272028
Revenue per Employee$12.3M---
Opex per Employee$8.1M---
G&A Expenses to Revenue52%56%53%52%
Opex to Revenue65%69%64%65%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Senvest Capital Competitors

Senvest Capital competitors include Platinum Capital, Wereldhave Belgium, Mogan Enerji, Qualitas Real Estate, Noah Holdings, RTW Biotech Opportunities, Kuyaş Yatırım, CBRE Clarion Glb Real Est, Thornburg Inc Builder and Regal Partners.

Most Senvest Capital public comparables operate across Asset Management and PE & VC.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Platinum Capital47.0x---
Wereldhave Belgium9.9x13.2x15.7x-
Mogan Enerji5.7x-14.5x-
Qualitas Real Estate-13.4x-16.1x
Noah Holdings(0.1x)(0.1x)(0.4x)(0.4x)
RTW Biotech Opportunities2.8x---
Kuyaş Yatırım130.9x-100.9x-
CBRE Clarion Glb Real Est54.0x---

This data is available for Pro users. Sign up to see all Senvest Capital competitors and their valuation data.

Start Free Trial

Investments by Senvest Capital

Senvest Capital has invested in 6 companies to date.

Latest investment by Senvest Capital was on February 12th 2025. Senvest Capital invested in Breakthrough in their $600K Pre-seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Senvest Capital

Breakthrough
Biolinq
Tasso
AIStorm
Description
Breakthrough is a New York-based sales enablement platform founded in 2022 that uses AI to generate personalized prospect outreach strategies. The tool analyzes buyer data from CRM systems like Salesforce to recommend messaging, timing, and objection handling for B2B sales cycles. It integrates with Gong and Outreach for real-time coaching during calls. Breakthrough serves revenue teams at companies including ZoomInfo and HubSpot, focusing on enterprise software sales.
Biolinq is a San Diego-based digital health company developing minimally invasive biosensors for continuous biomarker monitoring. Their electrochemical skin patches analyze interstitial fluid for glucose, lactate, and electrolytes, targeting diabetes management and athletic performance. Backed by J&J and others, the platform integrates with apps for real-time health data.
Tasso is a Seattle-based medical device company pioneering at-home blood collection for diagnostics. Its HemoLink device enables capillary blood sampling with 200 microliters yield in under 3 minutes, compatible with lab analyzers for therapeutic drug monitoring and wellness testing. FDA-cleared since 2020, Tasso partners with Quest Diagnostics and Everlywell, shipping over 50,000 units to consumers and clinics. Founded in 2015, the firm raised $15 million in Series A funding and operates in the US with clinical trials in Europe for chronic disease management.
AIStorm is a San Jose-headquartered developer of ultra-low-power analog AI chipsets that process sensor data at the edge for always-on applications. The IMPULSE platform combines mixed-signal compute-in-memory architecture to handle image, audio, and radar inputs directly from devices like cameras and microphones. AIStorm targets IoT devices, wearables, and automotive systems, partnering with Qualcomm for integration. Founded in 2016, it delivers inference speeds up to 100 TOPS per watt with sub-milliwatt power consumption for tasks like object detection and voice recognition.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Los Angeles, CA
San Diego, CA
Seattle, WA
San Jose, CA
Deal Date12 Feb 20254 Apr 202416 Dec 202115 Dec 2020
RoundPre-seedUndisclosed stageSeries BSeries B
Raised$600K$58M$100M$16M
InvestorsSenvest CapitalAlpha Wave Ventures; Aphelion Capital; AXA Investment Managers; Features Capital; Global Health Investment Corporation; Niterra Ventures; Pegasus Tech Ventures; RiverVest; Senvest Capital; Taisho Pharmaceutical HoldingsCedars-Sinai Accelerator; D. E. Shaw & Co.; Foresite Capital; Hambrecht Ducera Growth Ventures; InCube Ventures; J2 Ventures; Merck Global Health Innovation Fund; RA Capital Management; Senvest Capital; SIB Innovations- und BeteiligungsgesellschaftAsustek Computer; Egis Technology; Knowles; Meyer; Senvest Capital
Valuationundisclosedundisclosed$425Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Senvest Capital investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Senvest Capital

When was Senvest Capital founded?Senvest Capital was founded in 1968.
Where is Senvest Capital headquartered?Senvest Capital is headquartered in Canada.
How many employees does Senvest Capital have?As of today, Senvest Capital has over 30 employees.
Is Senvest Capital publicly listed?Yes, Senvest Capital is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of Senvest Capital?Senvest Capital trades under SEC ticker.
When did Senvest Capital go public?Senvest Capital went public in 1983.
Who are competitors of Senvest Capital?Senvest Capital main competitors include Platinum Capital, Wereldhave Belgium, Mogan Enerji, Qualitas Real Estate, Noah Holdings, RTW Biotech Opportunities, Kuyaş Yatırım, CBRE Clarion Glb Real Est, Thornburg Inc Builder, Regal Partners.
What is the current market cap of Senvest Capital?Senvest Capital's current market cap is $702M.
What is the current revenue of Senvest Capital?Senvest Capital's last fiscal year revenue is $370M.
What is the current EV/Revenue multiple of Senvest Capital?Current revenue multiple of Senvest Capital is 1.9x.
Is Senvest Capital profitable?No, Senvest Capital is not profitable.
How many companies Senvest Capital has acquired to date?Senvest Capital hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Senvest Capital has invested to date?As of June 2026, Senvest Capital has invested in 6 companies.
In what companies Senvest Capital invested in?Senvest Capital invested in Tasso, Biolinq, Bigfoot Biomedical, AIStorm, Unlimited, and Breakthrough.

See public comps similar to Senvest Capital

Lists including Senvest Capital

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial